

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(#5)

In re application of:

ROBERT *et al.*

Appl. No.: 10/529,221

(U.S. Nat'l Phase of PCT/US03/30238)

Filed: September 26, 2003

For: **Targeted CD1d Molecules**

Confirmation No.: 2116

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 1843.0200001/EKS/AJK

**Preliminary Amendment and Submission of Sequence Listing**

***Mail Stop PCT***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks. This Preliminary Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification; and
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.